148 related articles for article (PubMed ID: 2120616)
1. Selegiline HC1: Selective MAO-type B inhibitor.
Koller WC; Giron LT
Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
[No Abstract] [Full Text] [Related]
2. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
3. MAO-B inhibitor know-how: back to the pharm.
Lewitt PA
Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
[No Abstract] [Full Text] [Related]
4. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
LeWitt PA
Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
[No Abstract] [Full Text] [Related]
5. MAO-B inhibitors in Parkinson's disease.
Olanow CW
Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
[No Abstract] [Full Text] [Related]
6. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
[TBL] [Abstract][Full Text] [Related]
7. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
8. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and neuronal rescue effects of selegiline: review.
Magyar K; Haberle D
Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
12. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
13. MAO inhibitors.
Keller D
Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
[No Abstract] [Full Text] [Related]
14. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
Lew MF
Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328
[TBL] [Abstract][Full Text] [Related]
15. MAO type B inhibitors as adjunct to L-dopa therapy.
Youdim MB; Finberg JP
Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
[No Abstract] [Full Text] [Related]
16. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
17. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
18. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
Li XM; Juorio AV; Paterson IA; Boulton AA
J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
[No Abstract] [Full Text] [Related]
19. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
Knoll J
Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]